- Rapid but uneven uptake: 41,488 of 2,266,202 episodes (1.83 per cent), with substantial state variation.
- By 2024 Medicaid was the primary payer, covering 71 per cent of long-acting injectable buprenorphine episodes.
- Most prescriptions were written by advanced practice clinicians, primarily nurse practitioners, comprising 62 per cent of long-acting injectable episodes.
Health Aff (Millwood). 2026 Jul;45(7):819-825. doi: 10.1377/hlthaff.2025.01584.
ABSTRACT
We analyzed nationwide IQVIA pharmacy buprenorphine prescription episodes to characterize patterns, prescribers, and payers of long-acting injectable buprenorphine during the period 2021-24. Among 2,266,202 episodes, 41,488 (1.83 percent) were identified as being initiated with long-acting injectables, varying greatly across states. By 2024, Medicaid emerged as the most likely payer (71 percent of episodes), and most long-acting injectable episodes were prescribed by advanced practice clinicians such as nurse practitioners (62 percent).
PMID:42413053 | DOI:10.1377/hlthaff.2025.01584
Share Evidence Blueprint

Search Google Scholar
Save as PDF

